is Relmada's lead drug candidate that has entered Phase 3 development for the treatment of MDD. It has the potential to be a once-daily, oral pill that blocks hyperactive NMDA receptor (NMDAR) channels associated with MDD, while maintaining the physiological activity of glutamate, the major excitatory neurotransmitter in the brain.

3. What is the significance of neural plasticity in Relmada's approach to treating CNS disorders?

Question

is Relmada's lead drug candidate that has entered Phase 3 development for the treatment of MDD. It has the potential to be a once-daily, oral pill that blocks hyperactive NMDA receptor (NMDAR) channels associated with MDD, while maintaining the physiological activity of glutamate, the major excitatory neurotransmitter in the brain.

3. What is the significance of neural plasticity in Relmada's approach to treating CNS disorders?

Accepted Answer

Relmada's approach to treating CNS disorders is based on the understanding that the brain continuously develops new neural connections in response to the environment, a process known as neural plasticity. By understanding the potential of neural plasticity in clinical settings, Relmada aims to unlock new patterns for the treatment of central nervous system disorders, including MDD.

Voyager DB

Contact Research

Chrome Extension

Relmada Therapeutics, Inc

Company Overview

Company Name

Address

Website

Phone

Approx. Annual Revenue

Employees

Established

About Relmada Therapeutics, Inc

More Companies in Florida

Frequently Asked Questions about Relmada Therapeutics, Inc

Categories

Technologies Used

Social Profiles

Key Decision Makers